KRAS and neoplasm: While most PDAC cases are driven by canonical gain-of-function KRAS mutations [47], ConDoR reveals that the tumor analyzed here is driven by a truncal BRCA2 stop-gained mutation (p.Y600*), which likely inactivated the BRCA2 protein, a tumor suppressor essential for homologous recombination repair [48].